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More Than the Sum of Its Parts: Meta-Analysis and Its Potential to Discover
Sources of Heterogeneity in Psychosomatic Medicine
LINEKE M. TAK, MD, PHD, ANNA MEIJER, MSC, ANDIAPPAN MANOHARAN, MSC, PETER DE JONGE, PHD,
AND JUDITH G. M. ROSMALEN, PHD
Meta-analyses may contribute to more reliable knowledge about the existence of certain relations in the area of psychosomatic
research. Surprisingly, the increasing popularity of meta-analysis is not reflected in the number of meta-analyses of observational
studies published in Psychosomatic Medicine. This may be due to the specific difficulties that apply to meta-analyses of
observational research. The aim of this paper is to provide a nontechnical overview of the principles of meta-analysis applied to
observational research. We will highlight general principles of meta-analysis and discuss the major threats to its validity, with an
emphasis on its specific merits and pitfalls for psychosomatic research, using several examples. We conclude that meta-analysis is
a relatively simple technique, leaving little reason for not routinely applying it when performing a systematic review. An adequately
conducted meta-analysis may not only provide a summary estimate of a certain association, but it has additional value in
discovering relevant confounders, mediators, and moderators, as well as identifying areas of research that require more attention.
Key words: meta-analysis, effect size, heterogeneity, meta-regression, mega-analysis, observational studies.
BMI body mass index; IL interleukin; IPD individual patient
data; OR  odds ratio; PTSD  posttraumatic stress disorder;
SEM  standard error of the mean; SMD  standardized mean
difference.
INTRODUCTION
Meta-analysis is a statistical procedure that integrates sev-eral studies concerning a certain research question to
reach a more secure conclusion. State-of-the-art meta-analyses
have the potential to provide a more objective appraisal of the
evidence than traditional narrative reviews. They can reveal
that repeated results in the same direction across several
studies, even if not one is significant, can be much more
powerful evidence than a single significant result from an
individual study (1). In addition, meta-analyses can provide
insight into why different studies have found different results.
Furthermore, whereas adequately powered, randomized, con-
trolled trials have a relatively high positive predictive value of
reflecting the true relationship, this value drops for research
findings of observational studies (2). Meta-analysis of re-
ported associations in observational studies may raise the
positive predictive value of the true relationship. Finally,
meta-analysis may identify areas of research that need more
investigation, for example, based on results of subgroup or
sensitivity analyses (3,4).
Meta-analysis is a particularly useful procedure in psycho-
somatic research. Many studies in this field meet characteris-
tics that contribute to the risk of nonreplication, such as having
small sample sizes, retrieving small effect sizes, testing a large
number of relationships without clear rationale, and having
large flexibility in designs, definitions, outcomes, and analyt-
ical methods (2,5). In spite of this, the sharply increased
number of published meta-analyses in general medicine (6,7)
is not reflected in Psychosomatic Medicine, where the average
number of meta-analyses published is stable at around two per
year (Table 1). Since 2000, 15 of 16 meta-analyses published
in Psychosomatic Medicine were purely based on observa-
tional research (and the other one was a combination of
observational and intervention research) (8), whereas this was
the case for only one fourth of the 127 meta-analyses pub-
lished in this time period in the Journal of the American
Medical Association as an example of a general medical
journal. In the light of certain difficulties that are associated
with meta-analyses of observational studies, most importantly
the risk to produce very precise but equally spurious results
(9), the relative low number of meta-analyses in Psychoso-
matic Medicine may not be surprising.
Since the last review on meta-analysis in Psychosomatic
Medicine almost two decades ago (10), new techniques, pro-
cedures, and recommendations have become available (6).
The current paper provides an update in the form of a non-
technical overview of the general principles of meta-analysis
to readers with a basic knowledge of statistics. We will high-
light the general principles of meta-analysis and discuss the
major threats to its validity, with an emphasis on its specific
merits and pitfalls for observational, psychosomatic research.
Our aim is that, after reading our paper, researchers should be
able to critically interpret meta-analyses performed by others
or are encouraged to perform a meta-analysis themselves.
Inclusion of Studies
Literature Search
In searching literature for a meta-analysis, the goal is to
include as many of the existing relevant studies as possible in
a reproducible manner. Meta-analyses on psychosomatic re-
search should use at least the literature databases Medline and
Embase. In addition, other, more subject-specific databases
can be searched, depending on the research question (e.g.,
PsycINFO, CENTRAL, CINAHL, ISI Science and Social
Science Citation Index, Cochrane Library). Each database has
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specific search possibilities, and most databases provide tuto-
rials. Databases often use key words, but free text should also
be searched (11,12). The search should be conducted without
language restrictions to reduce the risk of language bias
(13,14). Because searching the literature is almost a specialty
in itself and errors in search strategies are common (15),
additional consultation of a librarian may be worth consider-
ing. The probability that research findings are published is
influenced by the nature and the direction of the results.
Significant research findings are overrepresented, whereas
results conflicting with the prevailing beliefs about the asso-
ciation are underrepresented (16). Searching for unpublished
studies is thus important to achieve a representative sample of
the work available in the research area under study, but it
requires considerable effort. Unpublished findings may, for
example, be revealed by asking relevant research groups for
any unpublished results or checking dissertation databases
(e.g., Dissertation Abstracts Online, ProQuest Dissertations,
and Theses).
Selection of Relevant Studies
Articles are selected for inclusion based on a predesigned
protocol containing inclusion criteria specifying the type of
subjects, exposure, outcomes, and type of study (11,12,17).
This is preferably done by two independent reviewers, as they
select on average 9% more studies than one (18). One partic-
ular problem in the selection process is the fact that several
articles with different first authors may report on the same
study, or on partly overlapping data. This problem may espe-
cially occur in observational studies that gather information on
a large number of variables over a relatively long period of
time, resulting in more than one publication on a single study.
Just like the search strategy, the selection process should be
reported in detail.
Methodological Quality
Critical appraisal of the methodological quality of primary
studies is an essential feature of meta-analysis. Good meth-
odological quality can be defined as having a design that
minimizes bias in the estimation of the association under
study. Critical appraisal checklists or scales (“tools”) can be
used as a threshold for inclusion of studies, or preferably, the
meta-analysis can be repeated excluding low-quality studies to
assess whether results would change. Although there is a
plethora of tools for assessing quality of intervention trials,
consensus on the ideal tool for assessing methodological qual-
ity of observational studies is currently not available (19).
Major domains that should be incorporated in every observa-
tional studies quality tool are selection of participants, mea-
surement of dependent variables, and control for confounding.
The type of tool used to assess quality can dramatically
influence the interpretation of meta-analyses (20). To de-
velop a valid tool, experts in the field could be consulted
and development of the tool should be clearly stated. Re-
liability of the tool can be assessed by using at least two
independent raters to score the individual papers, and in-
terrater agreement statistics should be reported. Research-
ers should be aware that using a quality tool inevitably
introduces subjectivity, such as the decisions on which items
to include and on the scoring rules for each quality item. When
developing a quality tool, general items for quality of report-
ing can be used, such as consensus guidelines on reporting of
randomized trials, CONSORT (21); diagnostic tests, STARD
(22); or observational studies in epidemiology, STROBE (23).
Recommendations (24) for adequate reporting of case-control
studies in the psychiatric setting have also been made, which
are largely applicable to observational psychosomatic re-
search. Additionally, researchers can include specific items
that are pivotal for good quality studies in their field. Assess-
ing sources of bias is a crucial but equally complex function of
a quality tool, because distinguishing quality of reporting and
quality of the actual study design is often not possible. Not-
withstanding some degree of uncertainty about the validity of
comparing study quality, quality tools specifically designed
for a meta-analysis of a certain topic under study may addi-
tionally serve as a guideline for conducting high-quality future
research. An example of a quality tool for meta-analysis of
observational studies in the psychosomatic area is one devel-
oped for studies on cardiac vagal activity in functional somatic
syndromes. Experts in the field were asked to review this
quality tool that includes items such as whether the functional
somatic syndrome has been reliably assessed; whether the
measurement of cardiac vagal activity has been reported in
appropriate unit, and whether specific covariates, such as age,
gender, body mass index (BMI), depression, and medication
use, have been assessed or adjusted for (25). In this meta-
analysis, it could not be proven that study quality accounted
for the mixed findings. It was advised, however, that future
research adhering to the proposed quality criteria may provide
a more definite answer on the question whether lower cardiac
vagal activity is involved in the etiology of functional somatic
syndromes. The assessment of methodological quality should
be considered as a routine procedure in meta-analysis.
Meta-Analysis Performance
Effect Size per Study
The basic information needed for a meta-analysis is the
effect size per study, which is the measure of the magnitude
(strength) of the association between two variables. Informa-
tion needed to calculate this effect size consists of a summary
measure and a measure of its precision (standard error or 95%
confidence interval). Widely used summary measures are the
correlation coefficient, odds ratio (OR), and standardized
mean difference (SMD), but mean difference, risk ratio, rate
ratio, hazard ratio, proportion, etc. are also possible summary
measures. In case of variability in reported effects, several
formulas for converting test statistics (such as t, 2, Z, or F
values, or their associated p levels) to effect size estimates
(such as Cohen’s d, OR, and correlation coefficients) and
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formulas for converting effect size estimators from one type to
another are available (26,27).
In the area of psychosomatic research, however, there may
be specific problems concerning retrieving effect sizes, as
different measures for the same construct are often applied in
the original studies. For example, in a meta-analysis on de-
pression and pain perception thresholds, effect sizes had to be
calculated from studies using different methods to measure
depression (Beck Depression Inventory, Hamilton Depression
Scale, or diagnostic criteria according to Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition) and pain
perception (cold-, heat-, pressor-, ischemic-, and electrical
stimuli) (28). Effect sizes based on the standard deviation
(SD), such as the SMD, provide a solution to this problem.
The SMD is calculated as the difference between the means of
the cases and controls divided by the pooled SD. Although the
SMD is the predominantly used effect size in social sciences
(1), it has been disputed by others (29). The use of SMDs is
criticized because of the underlying assumption that the dif-
ferent scales from which the SMD is calculated are linearly
related. Although this is a limitation of the SMD, calculating
SMDs is sometimes the only feasible option (e.g., in cross-
sectional case-control studies).
Correlation Coefficients and SMDs
When an effect size is applied to continuous variables,
commonly used effect size indices are the r family and the d
family (1). The r effect size family includes all types of
correlation coefficients (i.e., r, phi, rho) and is preferably used
when the studies comprising the meta-analysis primarily re-
port the correlation between variables (e.g., continuously mea-
sured psychological factors, such as anger or hostility, and
development of hypertension in population cohorts) (30). The
d effect size family provides SMDs and is preferably used
when the studies comprising the meta-analysis primarily re-
port analyses of variance and t test comparisons between
groups on continuous variables (e.g., cardiovascular activity in
posttraumatic stress disorder [PTSD] patients versus healthy
controls) (31). Cohen’s d and Hedges’s g are two widely used
examples of an SMD. When sample sizes are small, Cohen’s
d may produce estimates of the population effect size that
are slightly too large (32). Therefore, Cohen’s d is somet-
imes adjusted by the following formula ( [(n cases  n
controls  2)/(n cases  n controls)]  d), which results in
Hedges’s g (33). For example, a study compared cardiac vagal
activity in 11 patients with chronic fatigue syndrome (2.75 SD
1.39 ln ms2) with 11 healthy controls (3.09 SD 0.56 ln ms2)
(34). It can be calculated that Cohen’s d  0.34 (95%
confidence interval [CI], 0.00 to 1.14). In this small sample,
correction leads to a small attenuation of the effect size,
namely, Hedges’s g   [(11  11–2)/(11  11)] 
0.34  0.32. The r of this association is .17 based on
Cohen’s d (r   [d2)/]d2)  4), indicating that explained
variance (r2) chronic fatigue syndrome by lower cardiac vagal
activity in this study is .172  2.8% (and 2.5% when using
Hedges’s g).
Occasionally, descriptive or inferential statistics needed to
compute an effect size are not reported. Conservative ap-
proaches to impute an effect size for missing values exist. For
example, when a significant association was reported in the
primary study, a conservative effect size assuming that p was
equivalent to .05 can be computed. In case there was no
significant association, an effect size of 0.00 can be imputed.
Several methods to impute missing data in meta-analyses have
been discussed elsewhere (35).
The magnitude of effect sizes is often interpreted by using
Cohen’s conventions, in which an SMD of 0.0 means no
difference, 0.2 represents a small difference, 0.5 represents a
moderate difference, and 0.8 represents a large difference
(36). Inherent to the multifactorially caused conditions typi-
cally under investigation in psychosomatic research, effect
sizes are usually small. For example, the median Cohen’s d in
the studies listed in Table 1 is 0.34 (interquartile range,
0.27–0.55). The final evaluation of the meaning of the effect
size, nevertheless, requires individual judgment regarding the
specific topic under study, in which the consequence of the
outcome or the possibility of prevention and treatment are also
taken into account.
ORs and Other Probability Effect Sizes
Probability effect sizes are usually given in studies with a
binary outcome, such as in studies with disease versus no
disease or mortality versus no mortality as end point. The
selection of the appropriate summary statistic is a subject of
debate due to conflicts in the relative importance of mathe-
matical properties and the ability to interpret results intuitively
(6). Recommendations (37) on how to choose between ORs,
risk differences, risk ratios, and other relative measures have
been documented elsewhere. Frequently, ORs are reported,
such as in a meta-analysis on the association between depres-
sion and cardiovascular disease and mortality (38–40). The
odds are the number of patients who fulfill the criteria for a
given end point divided by the number of patients who do not.
The OR relatively easily allows combining data and testing for
statistical significance. Although relative effect measures are
generally used for summarizing the evidence, absolute mea-
sures, such as the absolute risk reduction or the number of
patients needed to treat to prevent one event, are more useful
when applying the results in a concrete clinical or public
health situation and should be recalculated from the relative
summary estimates (4,41). Also, effect sizes should be com-
pared with the effects of well-established risk factors in the
field to determine their (clinical) importance. For example, the
influence of depression as a risk factor for the development of
coronary disease in community samples without clinically
apparent heart disease was considered similar to published
effect sizes of the widely accepted risk factor smoking (40).
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Pooling of Effect Sizes
Methods for calculating the summary estimate by combin-
ing the effect sizes of the individual studies use a weighted
average of the results, in which larger studies have more
influence than smaller ones. This study weight is computed
from the variance or squared standard error of the mean
(SEM): weight factor (w)  1/SEM2. The summary estimate
in a meta-analysis is the mean weighted effect size, calculated
by the sum of the products of effect size and weight per study,
divided by the sum of all study weights ( effect size 
w/w). The accompanying 95% CI can be calculated with the
following formula: 1.96 1/[SEM of summary estimate]2.
It is assumed that each value contributing to the summary
estimate is statistically independent of the others. An exten-
sive overview of the statistical basis of formal meta-analysis
has been provided by others (42). The meta-analysis can be
repeated using different methods to assess whether the same
results are achieved and the summary estimate is robust to the
decisions made to obtain it.
Software
Programs designed for the statistical pooling of data in
meta-analysis are available, and most general statistical pack-
ages include meta-analysis options. Most of these programs
are relatively easy to master and offer tutorials and a help
function. Moreover, many programs and add-ons to statistical
packages are freely available on the Internet. In general,
programs offer at least basic statistical methods and graphical
presentations, and commercial software is not necessarily
better than free software (43). Differences may exist in statis-
tical methods, usability, graphics, and whether or not the
software is being maintained. Some of the most-used pro-
grams will be discussed and links to more information will be
provided (Table 2). The basic results obtained from the dif-
ferent software packages are essentially the same (44). The
studies of Bax et al. (43) and Egger et al. (44) provide an
overview and comparison of some meta-analysis programs.
Fixed Effect Versus Random Effects Models
When pooling the effects of all studies included in the
meta-analysis, the fixed effect model or the random effects
model can be used. The fixed effect model assumes that the
samples of all studies are based on the same population and
that the same underlying effect is thus measured in all studies
(i.e., there is one true effect size). In this method, between-
study variation is assumed to be due to sampling error. A
disadvantage of the fixed effect model is that it is highly
unlikely that studies do measure the same underlying effect,
especially in epidemiologic research (45). The random effects
model, in contrast, assumes that each sample comes from a
TABLE 2. Overview of Software Packages for Meta-Analysis
Software Availability Web Site





Johnson BT, editor. DSTAT 1.10: Software for the Meta-Analytic Review of Research Literature. Hillsdale,
NJ: Lawrence Erlbaum; 1993
Easy MA Free http://www.spc.univ-Lyon1.fr/	mcu/easyma/
Fast*Pro Commercial Eddy DM, Hasselblad V, Schachter R. Meta-Analysis by the Confidence Interval Method. The Statistical
SynthesisoOf Evidence. San Diego: Academic Press; 1992
META Commercial http://userpage.fu-berlin.de/health/meta_e.htm
Schwarzer R. Meta-Analysis Programs (Computer Program and Manual) v. 5.3. Berlin, West Germany:




Meta Stat Free http://ericae.net/meta/metastat.htm









True epistat Epistat Services, Richardson, TX
Gustafson TL. True Epistat Reference Manual. Richardson, TX: Epistat Services; 1994
WEasy MA Commercial www.clininfo.fr/uk/index.html
Chevarier P, Cucherat M, Freiburger T, Maupas J, Visele N, Buguard F, Bazog P. WeasyMA. Lyon:
ClinInfo; 2000
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different population and that the effects in these populations
may also differ. Between-study variation is assumed to be due
to differences in the underlying effects in the samples. The
random effects model gives the average effect of all studies
(12). A disadvantage of the random effects model is that it
assumes the studies are a random sample of effect sizes and
that between-study variation is distributed normally (16). This
is often not the case, for example, as a result of publication
bias (45). An advantage of the random effects model is that it
permits to generalize to studies that might be done in the
future.
In the fixed effect model, the inverse variance method is
used to pool effect sizes based on continuous data, such as
mean differences or SMDs. To pool effect sizes based on
binary data, such as ORs and relative risk, the Mantel-
Haenszel’s method can be used (46), or the Peto method in
case of pooling ORs of studies with balanced arm sizes,
small intervention effects, or rare events (47). When the
effect sizes are pooled using a random effects model, the
DerSimonian-Laird method is used both for effect sizes-
based binary and continuous data (48).
The random effects model is more conservative than the
fixed effect model and is used when heterogeneity is sus-
pected (4). Although tests for heterogeneity are often used to
determine whether a fixed or random effects model must be
used, these tests are often underpowered, and deciding on the
model should therefore be primarily based on characteristics
of included studies (12,16). In general, the random effects
model is more plausible, and using the fixed effect model
should only be done when this can be firmly justified on
theoretical grounds. An example of how using random effects
versus fixed effect analysis can change the summary estimate
and conclusion is found in a meta-analysis on cortisol levels in
patients with functional somatic syndromes (49). The fixed
effect model shows significantly lower cortisol in patients
with functional somatic syndromes compared with healthy
controls (SMD, 0.12; 95% CI, 0.18 to 0.05; p  .01),
whereas the more appropriate random effects model shows a
wider CI and no statistical significant difference (SMD,
0.07; 95% CI, 0.17 to 0.04; p  .24).
Forest Plot
The main results of a meta-analysis are usually represented in
a forest plot. Forest plots graphically display information on the
individual studies included in the meta-analysis, the amount of
variation between studies, and an overall estimate of the results of
all studies combined (Fig. 1) (50). ORs are best plotted on
logarithmic scales, as this enables ORs of the same magnitude
but opposite directions—for example, 0.1 and 10.0—to be equi-
distant from 1.0 (4). Next to the forest plot, the basic details of
each study supplying data should be presented, such as primary
author, year of study, design, crude data, derived summary esti-
mate and measure of its precision, allowing readers to evaluate
the summaries against what was presented in original reports, or
to repeat the meta-analysis at the same time making other deci-
sions or using other techniques.
Heterogeneity
Heterogeneity in meta-analysis means that included studies
differ considerably on one or several important aspects, which
may affect comparability of their results and which may have
caused differences in results. Studies can be different in a)
biological, psychological, or clinical variables, including gen-
der, age, characteristics of study participants, severity of ex-
posure, and condition or disease; b) methodological variables,
including study design, measurement procedures, extent of
control for confounding, and response measures; and c) mis-
cellaneous variables, including year of publication, character-
istics of the authors, and funding.
The presence of heterogeneity can be calculated statisti-
cally (51). The most used measures are the Q statistic, I2, and
tau-squared (2). To begin with, the Q statistic (also called
Cochran’s 2 statistic) is a 2 test calculating whether varia-
tion in study results is due to chance or whether variation is
due to systematic underlying differences and the null hypoth-
esis should be rejected. A value of Q similar to the degrees of
freedom in the analysis indicates little heterogeneity. When it
is considerably higher, and the p is .10, this indicates het-
erogeneity (52). The Q statistic, however, has a number of
limitations. The Q statistic has low power when a single study
largely contributes to the mean weighted effect size (16). It
Figure 1. Example of a forest plot on the prognostic value of depression on cardiovascular mortality. Odds ratios are plotted on the logarithmic scale. OR 
odds ratio; CI  confidence interval. Reprinted with permission from Van Melle et al (38).
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also has low power when included studies are small or when
there are few studies, whereas this test may detect heteroge-
neity even though it is not substantial when many studies are
included (12). In the studies presented in Table 1, meta-
analyses in which the Q test was not significant were usually
based on a small number of primary studies (10), whereas
the Q test was significant in all meta-analyses with a relatively
large number of included primary studies (
30). This implies
that heterogeneity can be considered the rule, rather than the
exception, in meta-analyses published in Psychosomatic Med-
icine. A second measure of heterogeneity is the I2 statistic,
which is a derivative of Q. This statistic gives the percentage
of variability in results that is caused by heterogeneity rather
than coincidence (12). Generally, an I2 of 
50% indicates
considerable heterogeneity. A third statistic that is often used
to report heterogeneity is 2. This is the variance of the true
effect size; thus, there is no heterogeneity when this statistic is
0 (45). There are several more statistics that assess heteroge-
neity, some specific to the type of effect measure (16).
However, because of problems with power and accuracy,
when statistical tests of heterogeneity indicate that the null
hypothesis of no heterogeneity holds, this does not indisput-
ably prove that studies are completely homogeneous (16). It
should still always be investigated whether studies have
important clinical and methodological differences. When het-
erogeneity is suspected, this must be accounted for in the
statistical analysis and mentioned in the discussion. Usually,
the presence of heterogeneity is considered to be a negative
aspect of meta-analysis, because it makes the results of the
meta-analysis difficult to interpret (16) and suggests that sam-
ples may be too different to be combined. However, as no
widely accepted quantitative measure exists to grade hetero-
geneity, it may be better to examine it in a meta-analysis rather
than use it as a reason for not conducting one (53). Hetero-
geneity can also have advantages. If studies that are clinically
and methodologically heterogeneous lead to comparable re-
sults, this means that the results are generalizable to a wider
population. In addition, investigating sources of heterogeneity
can lead to a better understanding of associations, new hy-
potheses (11,16), and improvement of future research (54).
Moderator Analysis
Performing meta-analysis on subgroups based on charac-
teristics that potentially are responsible for differences in
effect sizes between studies can demonstrate whether the
strength of the summary estimate is influenced by these char-
acteristics. This procedure is referred to as moderator analysis.
For example, in a meta-analysis, a significant difference was
found in interleukin (IL)-6 serum levels between depressed
patients and controls, with an SMD of 0.25, 95% CI, 0.18–
0.31. However, the magnitude of the summary estimate of the
association between IL-6 and depression was largely attenu-
ated in studies that adjusted for BMI (n  22; SMD, 0.08;
95% CI, 0.02–0.13; p  .007) as compared with studies
without BMI adjustments (n  39; SMD, 0.50; 95% CI,
0.37–0.63; p  .001) (55).
Ideally, such subgroup analyses are planned in advance,
because investigating heterogeneity post hoc based on the data
from the meta-analysis itself can lead to overinclusion (16).
Providing a rationale for each moderator and giving due
consideration to the role that each moderator is intended to
play is essential (5). In case of post hoc subgroup analyses,
results should be reported as exploratory and the need for
replication should be mentioned (45). Particularly in observa-
tional studies, possible moderator analyses on confounders,
moderators, and mediators are an important part of the meta-
analysis. The extent to which putative confounders, modera-
tors, and mediators have been taken into account in original
studies is often highly variable, and extracting useful data is
not always possible.
Some difficulties may arise when using terminology
regarding confounders, moderators, and mediators. A vari-
able may be considered as a confounding or mediating
factor in the original study, but this variable is tested as a
moderator in the meta-analysis. For example, authors in the
previously mentioned meta-analysis on IL-6 and depression
proposed that depressive symptoms may facilitate weight gain
over time as a result of physical inactivity. In this pathway,
BMI may be a mediator in reality (in case depression leads to
weight gain and weight gain to inflammation), but it is re-
ferred to as a moderator of the effect size in the meta-analysis.
The difficulties faced in moderator analyses are many.
First, there is the risk of spurious findings due to multiple
testing. When the number of original studies in the meta-
analysis is small (i.e., n  10–15), there are insufficient
degrees of freedom to test more than one moderator variable
(56). Nevertheless, many more subgroup analyses are often per-
formed, as illustrated by some of the studies listed in Table 1.
Second, when moderating variables are continuous, they
have to be categorized to be able to perform a moderator
analysis. It is, however, often unknown how to define sub-
groups. Artificially grouping data into categories introduces
measurement error with an inevitable loss of power (5). Fur-
thermore, the arbitrariness of the choice of cut point may lead
to the undesirable temptation of trying more than one value
and choosing the one that gives the most satisfactory result
(41). Third, moderator analysis does not provide a statistical
test of the existence of a moderator effect. Fourth, one cannot
look at effect moderation at the same time keeping other
covariates constant. When two moderators are highly corre-
lated and the first causes changes in the effect size, a moder-
ator test for the second will likely also be significant, even
though this second moderator does not truly influence the
strength of the effect.
An example of difficulties in interpreting the results of
moderator analysis is a meta-analysis across 37 studies on
cortisol levels in patients with PTSD (57). Overall, cortisol
levels were not significantly different in PTSD patients com-
pared with controls (SMD, 0.12; 95% CI, 0.32 to 0.08l
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p  .24) (57). Figure 2 presents subgroup analyses (SMD and
95% CI are shown) based on several moderators. Although
there is no significant difference in cortisol between PTSD
patients and controls in the primary summary estimates, sig-
nificantly lower levels of cortisol are found in females with
PTSD compared with female controls (gender is a moderator),
in patients with PTSD with physical or sexual abuse compared
with controls (trauma type is a moderator), and in PTSD
patients when they are compared with controls without trauma
exposure, as opposed to controls with trauma exposure but
without PTSD (exposure status of control group is a moder-
ator). However, as the authors mentioned, it is not possible to
disentangle whether those moderators act separately from
each other. For example, the association between female gen-
der and lower cortisol could be explained by a larger preva-
lence of sexual abuse in women. In this case, meta-regression
could be a possible solution to further elucidate the indepen-
dent contribution of those factors.
Meta-Regression
Meta-regression is a regression-based analysis that aims to
test for study heterogeneity by associating study characteris-
tics with study outcome. Typically, the independent variables
(predictors) are characteristics of each study, such as partici-
pants’ mean age, proportion of women, or follow-up duration.
The dependent (outcome) variable is the study effect size,
such as the SMD or log OR. The procedure for multivariable
meta-regression closely follows conventional regression anal-
ysis, the only difference being that a variable equal to the
inverse variance (i.e., the study weight) has to be used as case
weight to perform a weighted regression. Meta-regression can
be used to explain heterogeneity and provides the possibility
to simultaneously assess multiple characteristics. Again, the
fixed effect or random effects model can be used for meta-
regression. The full range of regression models and methods
(i.e., linear or logistic regression, testing interactions, model
fitting statistics) can be employed (29). For example, in a
meta-analysis on placebo response in patients with chronic
fatigue, it was found that the placebo response was higher in
interventions based on immunological assumptions compared
with interventions based on psychological assumptions. The
authors hypothesized that this difference could be explained
by higher expectations of patients on interventions assuming
physical causation as opposed to interventions assuming psy-
chological causation. Alternatively, they also considered the
possibility that systematic differences between immunological
and psychological trials, such as illness duration, placebo type,
and duration of follow-up, could explain the larger placebo
effect in immunological trials. In a meta-regression, however,
only intervention type (i.e., psychological or immunological)
set out to be significantly associated with a stronger placebo
response (p  .03), independent from all other factors (8).
Some problems affect the validity and reliability of meta-
regression. Primarily, meta-regression is prone to inflate false-
positive rates when heterogeneity is present, when there are
few studies, and when there are many covariates. Consider the
case of two studies producing effect estimates with nonover-
lapping CIs: any covariate whose value differs between these
studies will be significantly related to the heterogeneity
among the studies, and hence, a potential explanation of it,
although this explanation could be entirely spurious (58).
Furthermore, it is unclear how many covariates can reliably be
investigated without the risk of overfitting, and how this
depends on the number of studies, the extent of the heteroge-
neity, and the relative weights of the different studies. Rules of
thumb for conventional regression analyses (10–15 observa-
tions per covariate assessed, for instance) (56) are not directly
relevant to meta-regression, as this type of regression deals
with the complexities of heterogeneity and differential study
weights. To be on the safe side, meta-analysts who aim to
explore heterogeneity using meta-regression should minimize
the number of covariates investigated, select those justified
through scientific rationale, and specify them in advance (58).
Second, regarding translation of the results of the meta-
regression to individuals, the problem of aggregation bias
(“ecological fallacy”) may arise. This bias refers to the as-
sumption that individuals have the average characteristics of
Figure 2. Examples of moderator analyses in a meta-analysis on cortisol
and posttraumatic stress disorder (57). PTSD  posttraumatic stress disorder.
Reprinted with permission from the Royal College of Psychiatrists (57).
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the group to which they belong and, thus, that relationships
observed for groups necessarily hold for individuals. The
meta-regression analysis is conducted at the study level and does
not include the underlying patient-level variation. The relation-
ship between group means may not reflect the relationship be-
tween values of exposure and outcome in an individual, and
average quantities instead of person-specific quantities can lead
to erroneous conclusions (59). For example, suppose that coun-
tries with a high per capita income have high suicide rates.
Inferring that increasing personal income at the individual level is
also associated with suicide-related mortality can lead to errone-
ous conclusions, as within countries, suicide-related mortality
may be lower in high-income than in low-income persons. Thus,
when interesting findings are discovered using meta-regression,
person-level data from large cohort studies or trials may be
required for confirmation.
Alternatively, meta-analysis of individual patient data
(IPD) (also referred to as “mega-analysis”) could be consid-
ered, in which raw data from every primary study are obtained
and transformed to a common format. The strengths of IPD
meta-analysis, in general, are that the power is greatly en-
hanced by the larger number of subjects and that more sub-
group analyses can be done. More importantly, however, in
observational research, IPD can be used to adjust consistently
for confounders. Adjustment for confounders is usually im-
possible in common meta-analysis, as not all studies perform
the same adjustments in their analyses, and they report ad-
justed analyses in different ways. An example is the meta-
analysis on the impact of depression on mortality. In this
research, several moderator analyses, such as on measurement
instrument to assess depression or duration of follow-up, did
not explain heterogeneity (39). Also, the relative risk of mor-
tality was nearly the same in unadjusted and adjusted results,
and the amount of heterogeneity was not reduced. Authors
argued that one possible explanation for the heterogeneity of
the adjusted analyses may be the selection of risk factors,
which varied greatly from study to study. One possible solu-
tion to this problem would be to pool and reanalyze the
original data of all included studies. This can only be done
when different studies include comparable measures of the
variables to be adjusted for. A major obstacle of IPD meta-
analysis is that it is time-consuming and requires cooperation
between several research groups, which may not always be
attainable. In addition, variables that must be compared will
generally be measured using different instruments in the in-
dividual studies, and must therefore be harmonized before
analysis is possible. Information may be lost during this pro-
cess of harmonization. A good overview of the methodology
of IPD meta-analysis is given by Stewart and Clarke (60).
Interpretation of Meta-Analysis Findings
Sensitivity Analysis
The process of undertaking a meta-analysis inevitably in-
volves many more or less subjective decisions; sensitivity
analyses can be conducted to determine whether the assump-
tions or decisions made have a major effect on the result of the
meta-analysis. Thus, sensitivity analysis addresses the ques-
tion of whether the findings of the meta-analysis are robust to
the methods used to obtain them. Examples of sensitivity
analyses include assessing the influence of including studies
that were doubted to meet eligibility criteria, comparing fixed
effect with random effects models, comparing cohort and
case-control studies, adding conservative effect size estima-
tions for studies that did not provide adequate data to calculate
an effect size, or excluding outlying studies. Two other com-
monly performed sensitivity analyses are assessing the influ-
ence of methodological study quality of primary studies and
the influence of publication bias.
Methodological Quality Used in Interpreting
Meta-Analysis Results
It remains a matter of debate how the results of quality
assessment should be incorporated in the analysis and inter-
pretation of results of meta-analyses. Exploring the effects of
quality on the quantitative results by using quality as a weight-
ing factor has been discouraged (61). We recommend using
quality scores in a sensitivity analysis, which can demonstrate
whether the findings of the meta-analysis are different for
low- and high-quality studies. For example, sensitivity anal-
ysis in a meta-analysis on the association between positive
well-being and mortality in healthy populations indicated a
stronger association between positive psychological well-be-
ing and reduced mortality in high-quality studies compared
with low-quality studies (62). This sensitivity analysis, thus,
supports the validity of the overall finding that there is an
association.
Publication Bias
Publication bias in observational meta-analyses may lead to
inflated effect estimates that tend to be in the hypothesized
direction. Several approaches have been developed to assess
publication bias. The most well-known approach is the funnel
plot—a scatter graph in which, for each primary study, the
effect estimate is plotted against a measure of precision (such
as sample size, or preferably, the standard error of the effect
size) (63). It is expected that more precise studies report effect
estimates close to the true effect, whereas effect estimates
from less precise studies will scatter more widely. In the
absence of publication bias, the plot is expected to resemble a
funnel-like shape, which is symmetrical around the summary
estimate. In a meta-analysis on decreased cardiac vagal activ-
ity in functional somatic syndromes, the funnel plot was not
symmetric, as there is a gap where small studies with null
findings are expected (Fig. 3A). Funnel plots can be visually
interpreted, but this is subjective and the agreement between
raters and the association between graph ratings and publica-
tion bias is found to be poor (64). A test for funnel plot
asymmetry formally examines whether the association be-
tween estimated effects and a measure of study precision is
larger than might be expected to occur by chance. The prin-
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ciple is to relate the effect estimates to their SEM, and to test
the null hypothesis that the association is absent. There are
many tests for funnel plot asymmetry, which were compared
by Rucker and colleagues (65). Two of the most well-
known test are the Begg and Mazumdar adjusted rank
correlation test (66) and the regression asymmetry test of
Egger and colleagues (67). The Begg and Mazumdar test
(66) is based on a Kendall’s  rank correlation between the
standardized effect size and its SEM. The test of Egger et
al. (67) is based on a linear regression of the effect estimate
against its standard error, weighted by the inverse of the
variance of the effect estimates. However, the tests have
low power to detect funnel plot asymmetry and thus do not
exclude the presence of publication bias. Publication bias is
not the only reason for funnel plot asymmetry. Asymmetry
also arises because of small study effects—a tendency for the
effects estimated in smaller studies to differ from those in
larger studies (68). Small study effects occur because of
differences in methodological quality between larger and
smaller studies, heterogeneity between studies with different
sample sizes (small studies may more likely include selected
groups of patients), an effect modifier associated with study
precision, or merely chance (67,68). In addition, some effect
estimates (e.g., ORs and SMDs) are naturally correlated with
their standard errors and can produce spurious asymmetry in a
funnel plot (12). Another mathematical estimation of publica-
tion bias is provided by the fail safe N, which indicates the
number of new, unpublished, or unretrieved nonsignificant
studies that would be required to lower the significance of a
meta-analysis to nonsignificant. A fail safe N that is small,
particularly compared with the number of studies included in
the meta-analysis, indicates that the degree of confidence that
can be placed in the main conclusions of the meta-analysis is
low. The fail safe N has been criticized for two reasons. First,
it overemphasizes statistical significance. Second, it is based
on the addition of studies that have an average null effect,
whereas unpublished studies may also have an effect in the
opposite direction as the observed meta-analysis result (69).
An important question is how to proceed when publication
bias is suspected. A relatively simple approach to correct for
publication bias is the “trim and fill” method (70,71), avail-
able in most statistical meta-analysis programs. The principle
behind this method is to impute new studies to an asymmetric
funnel plot, followed by a meta-analysis that includes the
imputed studies. The method works by estimating the number
of studies on the right-hand side of the funnel plot that have no
counterpart on the left-hand side. Studies causing the asym-
metry are then “trimmed” from the right-hand side of the
funnel plot, possibly leading to a shift of the reestimated
summary estimate that may again create asymmetry. The
process is repeated until there is no residual asymmetry, after
which the trimmed studies are put back and their missing
counterparts are imputed or “filled” by replicating the oppo-
site side of the funnel plot with the mirror axis placed along
the adjusted summary estimate. The difference between the
original summary estimate and the summary estimate based
on the extended data set, including the imputed studies, is
assumed to indicate the degree of publication bias. An as-
sumption underlying the trim and fill method is that the
magnitude of the effect size, and not the p value, determines
the chance of publication. Moreover, this technique assumes
that publication bias leads to this simple form of funnel plot
asymmetry, and that missing effect size estimates are of the
same size as those observed in the opposite direction. Never-
Figure 3. A) Funnel plot (n  14) showing the correlation between the standardized mean difference (SMD) and its standard error (SEM) with pseudo 95%
confidence limits. The summary estimate reveals that cardiac vagal activity is significantly lower in patients with functional somatic disorders compared with
healthy controls (SMD, 0.32; 95% confidence interval [CI], 0.63 to 0.01; p  .04). B) Trimmed and filled funnel plot (n  19) showing the correlation
between the SMD and its SEM with pseudo 95% CI limits. Squares represent the studies that have been filled. The adjusted summary estimate reveals that cardiac
vagal activity is not significantly different in patients with functional somatic disorders compared with healthy controls (SMD, 0.01; 95% CI, 0.34 to 0.36;
p  .95). Reprinted, with minor modifications from Biol Psychol 2009;82:101–110, Tak LM, Riese H, De Bock GH, Manoharan A, Kok IC, Rosmalen JG. As
good as it gets? A meta-analysis and systematic review of methodological quality of heart rate variability studies in functional somatic disorders, with permission
from Elsevier. (25).
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theless, it has been shown that the use of the trim and fill
method can help to reduce the influence of publication bias on
the summary estimates, even though the performance of this
method decreases when heterogeneity increases (72). With
regard to the studies on cardiac vagal activity in functional
somatic syndromes, Egger’s test rejected the null hypothesis
that there was no funnel plot asymmetry (p  .01). The trim
and fill method resulted in a fill of five studies and a shift from
an initially significant summary estimate to a reestimated
summary estimate that was nonsignificant (Fig. 3B) (25). This
analysis points to the possibility that studies contradicting
prevailing beliefs of lower cardiac vagal activity in functional
somatic syndromes have not been published. The trim and fill
method is recommended to be used as a form of sensitivity
analysis of the summary estimate.
Controversy Around Meta-Analysis
There are a number of outspoken critics of meta-analysis.
Most points of criticism do not only apply to meta-analysis but
also to the entire field of observational research, such as the
risk of reporting bias, publication bias, confounding, and lack
of comparability between studies. Some even argue that meta-
analysis of observational studies should not be done at all,
because it would only reinforce the biases inherent to epide-
miologic research by creating significant but incorrect results
(73). In a properly performed meta-analysis, however, these
limitations can be dealt with in a sound way, as has been
discussed in this article. Some critics argue that the statistical
pooling of data in observational data are highly prone to bias
and spurious findings. Instead, it is suggested that it is more
important to thoroughly investigate causes of heterogeneity
(9). We agree that statistical combination of studies should not
generally be the main aim of systematic reviews of observa-
tional studies, especially as heterogeneity seems the rule rather
than the exception (Table 1). The thorough consideration of
possible sources of heterogeneity between studies, by using
moderator analysis, meta-regression, and sensitivity analysis
should be considered as more important features of meta-
analysis in this field. When there are still serious limitations to
the results of the meta-analysis, these can be discussed, and
interpretation can be adjusted accordingly. Thus, instead of
disputing the technique of meta-analysis itself, we feel its
undue reputation of providing the final answer should be
rectified.
Concluding Remarks
Many papers in Psychosomatic Medicine primarily are
observational studies aiming to answer etiological questions.
Apart from providing a summary estimate, the importance of
meta-analyses based on those studies also lies in the identifi-
cation of sources of bias, heterogeneity, generation of new
hypotheses, and the construct of guidelines to conduct better
research in the future. Rather than pretending to provide the
final, not debatable answer, meta-analysis relies on shared
subjectivity. Every analysis inevitably requires certain subjec-
tive decisions, but these decisions should be transparent and
explicit. The discussion of a meta-analysis should not simply
state the results of the statistical pooling, but it should also
discuss the level of certainty of the conclusions and any
limitations to the interpretation of the findings. Specific guide-
lines on adequate reporting of meta-analyses based on clinical
trials (i.e., preferred reporting items for systematic reviews
and meta-analyses [PRISMA]) or on observational studies
(i.e., Meta-analysis Of Observational Studies in Epidemiology
[MOOSE]) are available (74,75).
This review aimed to demonstrate that performing a meta-
analysis is a good way to gain more knowledge concerning a
specific research topic. We agree with Rosenthal and DiMat-
teo (1) when they stated that anyone who is considering a
review of the literature has little justification for not doing it
quantitatively, as the skills and training required for perform-
ing a high-quality meta-analysis are modest. We hope that the
number of meta-analyses in Psychosomatic Medicine will
increase, as they have the ability to produce more knowledge
than is provided by the sum of its parts.
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